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ABSTRACT
Background
Increasing systemic treatment and shortages of oncol-
ogy professionals in Canada require innovative ap-
proaches to the safe and effective delivery of
intravenous (IV) cancer treatment. We conducted a
systematic review of the clinical and scientific litera-
ture, and an environmental scan of models in Canada,
the United Kingdom, Australia, and New Zealand. We
then developed a framework for the organization and
delivery of IV systemic treatment.
Methods
The systematic review covered the MEDLINE, EMBASE,
CINAHL, and HealthStar databases. The environmen-
tal scan retrieved published and unpublished sources,
coupled with a free key word search using the Google
search engine. The Systemic Treatment Working Group
reviewed the evidence and developed a draft frame-
work using evidence-based analysis, existing recom-
mendations from various jurisdictions, and expert
opinion based on experience and consensus. The draft
was assessed by Ontario stakeholders and reviewed
and approved by Cancer Care Ontario.
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Results
The poor quantity and quality of the evidence necessi-
tated a consensus-derived model. That model com-
prises four levels of care determined by a regional
systemic treatment program and three integrated struc-
tures (integrated cancer programs, affiliate institutions,
and satellite institutions), each with a defined scope of
practice and a specific organizational framework.
Interpretation
New models of care are urgently required beyond large
centres, particularly in geographically remote or ru-
ral areas. Despite limited applicable evidence, the
development and successful implementation of this
framework is intended to create sustainable, accessi-
ble, quality care and to measurably improve patient
outcomes.
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1. INTRODUCTION
In Canada, cancer is a major cause of morbidity and
mortality, and the leading cause of potential years of
life lost. Increasing demands for cancer services re-
late directly to annual cancer incidence increases of
3%, resulting mainly from population growth and ag-
ing 1. Medical oncology consultations are increasing
by 10%–20% annually, and systemic treatment has in-
creased at an annual rate of 7%–10%, fuelled by new
evidence-based therapies that improve survival and
quality of life 2. Even more enhanced treatments areVANDENBERG et al.
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predicted 3. These treatments are often more complex
than those they replace, and they are delivered for
longer periods as the survival time with cancer—now
increasingly a chronic disease—lengthens.
Several provincial and national bodies have con-
vincingly demonstrated that ongoing clinical human re-
source shortages limit funding and filling of new
oncology positions 2,4–9. For example, the November
2005 Canadian Post-MD Education Registry revealed
that only 34 medical oncology residents and 8 fellows
are in oncology training for the entire country 5. Exac-
erbating this problem are the numbers of retiring phy-
sicians 6 and registered nurses 8 anticipated in Canada.
Given such changes, Canadian provinces need to
devise innovative ways to deliver safe and effective
systemic treatment in an ambulatory care setting for
people with cancer. The risks of not pursuing a revised
and sustainable model of systemic treatment delivery
include adoption of ad hoc and inconsistent local solu-
tions; cessation of service in some jurisdictions; and
inequalities in access to, and standards of, care.
The purpose of the present work was to provide a
practical framework to guide standardized delivery of
evidence-based systemic treatment in hospitals outside
regional cancer centres, with special consideration for
geographically dispersed regions. The primary goal of
the framework is to provide safe, evidence-based sys-
temic cancer treatment while maximizing the efficient
use of resources and implementing the principle of pa-
tient-centred care provided as close to home as possi-
ble. Service provision; complexity of care; safety,
accessibility, and quality across all care levels defined
from the patient, organization, and system perspective;
and appropriateness, transparency, and accountability
were all taken into consideration. Quality, research,
and education are interlinked and integral parts in the
regional delivery of safe systemic treatment, ensuring
the dissemination of new or improved evidence-based
standards in this rapidly changing field.
2. METHODS
2.1 Evidence Base
We used two core methodologies to develop this
framework:
￿ a systematic review of scientific and clinical re-
search evidence and
￿ an environmental scan of systemic treatment mod-
els developed in other jurisdictions.
The scientific and clinical literature was system-
atically searched for published and unpublished reports
pertaining to the organization and delivery of systemic
treatment. Published sources included the medical
databases MEDLINE (OVID, 1996 through June 2006),
EMBASE (OVID, 1996 through June 2006), CINAHL
(OVID, 1996 through June 2006), and HealthStar (OVID,
1996 through June 2006). The terms used were “anti-
neoplastic agents,” “chemotherapy,” “infusions intra-
venous,” and “neoplasms,” combined with “health fa-
cilities,” “organizational policy,” “continuity of patient
care,” “outpatient clinics,” “ambulatory care facilities,”
“hospitals rural,” “hospitals community,” “hospitals
general,” “health care facilities,” and “health care
policy”. Article bibliographies and personal files were
also searched for relevant evidence.
The environmental scan retrieved published and
unpublished sources (June 25–July 4, 2006) document-
ing systemic treatment delivery at hospitals outside a
larger cancer centre. Documents from countries with
health care systems similar to Canada’s (United King-
dom, Australia, and New Zealand) were considered.
In addition, a free keyword search was conducted
through the Internet Google search engine, and a search
was made for documents mentioned in the text or ref-
erences of identified reports.
The inclusion criteria were kept purposefully broad.
Any study design was considered if it provided evi-
dence on ways to deliver systemic treatment within
ambulatory care institutions. Outcomes of interest in-
cluded health care provider roles and education, serv-
ice type and complexity, service volumes, quality
assurance, facility requirements, and administrative
and organizational responsibilities. Specific details of
the development of the evidence base can be found
online at www.cancercare.on.ca/pdf/pebc12-10s.pdf 10.
2.2 Development of the Framework
The Regional Models of Care Systemic Treatment
Working Group, comprising medical oncologists, a Can-
cer Care Ontario regional vice president, a regional can-
cer program administrator, a systemic treatment satellite
nursing administrator, oncology nurses, administrators,
pharmacists, and other professionals, reviewed the evi-
dence and used a combination of evidence-based analy-
sis, existing recommendations from various jurisdictions,
and expert opinion based on experience and consensus
to develop the framework. Given that the quantity and
quality of evidence was generally poor, the panel agreed
upon the framework elements through consensus of ex-
pert opinion.
A draft framework document was circulated to 191
stakeholders in Ontario for feedback, with 89% of re-
spondents endorsing the framework and document rec-
ommendations. More details regarding the feedback
obtained can be found at www.cancercare.on.ca/pdf/
pebc12-10s.pdf 10. The document was also reviewed
and approved by Cancer Care Ontario’s Clinical Coun-
cil, Provincial Leadership Council, and Executive Team.
3. RESULTS
3.1 Evidence Base
Evidence on the current organization and delivery of
systemic treatment across Canada, the United Kingdom,PRACTICE GUIDELINE SERIES
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Australia, and New Zealand was gathered through a
systematic search of the literature and a scan of docu-
ments from organizations concerned with systemic
treatment quality practice. In Canada, the provinces of
British Columbia, Saskatchewan, and Nova Scotia
have instituted important initiatives 11–13. More details
of the evidentiary base considered by the panel can be
found at www.cancercare.on.ca/pdf/pebc12-10s.pdf 10.
3.2 Regional Models of Care for Systemic
Treatment
The Regional Model for Quality Systemic Treatment
(Figure 1) consists of a key set of fundamental ele-
ments and regional programs designed to implement,
monitor, and evaluate quality indicators related to the
delivery of safe, evidence-based, and patient-centred
care. The model is an organizational framework for
the delivery of systemic treatment within a regional
systemic therapy program (RSTP). The main goal of
the model is to facilitate the provision of appropriate
care in the appropriate setting within the appropriate
time frame for all patients, regardless of the geographic
location in which a patient receives systemic treatment.
The model is composed of three integrated structures—
integrated cancer programs (ICPs), affiliate institutions,
and satellite institutions—each with a defined scope
of practice.
The ICPs are multidisciplinary organizations that
provide complex cancer care and that conduct cancer
site–specific multidisciplinary care conferences (MCCs).
The MCCs discuss unusual cases, oversee quality as-
surance, and provide assistance on cases seen at the
RSTP level 1–4 facilities in their own ICP region. The
MCCs include surgical, radiation, and systemic therapy
oncologists, nurses, pharmacists, social workers, pa-
thologists, and radiologists. The ICPs provide leadership
in the development of local guidelines for their region;
they collect and assist in the analysis of outcome meas-
ures and quality indicators for funding, patient safety,
and program organization and efficiency; and they may
provide academic leadership, including educational
support and access to research.
Affiliate institutions have their own systemic treat-
ment programs, although they are linked through for-
mal agreements with the RSTP. Satellite institutions
have fewer oncology-related resources and have a for-
mal linkage to the RSTP for support in delivering sys-
temic treatment.
All regional partner institutions will participate in
the development of their RSTPs and will collaboratively
determine the appropriate configuration for their model,
including the formal linkages that will be required
among institutions. The complexity of care delivered
in each type of institution may vary; standards encom-
passing four institutional levels of care (levels 1–4) are
recommended for the delivery of systemic treatment,
with the level of complexity and the availability of
services differentiating one level from another. The
RSTP determines the appropriate level of care for each
institution. Levels are hierarchical, with the satellite
responsibilities being encompassed within the affiliate
and ICP levels. The designation of a level requires that
an institution meet all the standards for that level. As
individual institutions expand or focus their services,
the configuration of the model and the designation of
institutional levels may change, after consultation be-
tween the RSTP and the institution.
The successful implementation of the framework
is intended to create sustainable, accessible quality care
and to measurably improve patient outcomes. The four
levels and their standards are these:
￿ Level 4 (Satellite)
￿ Ambulatory facilities, nursing, pharmacy, and
physician support provided for the administra-
tion of low-risk to high-risk intravenous sys-
temic treatment under the direction of an
oncologist from an ICP or an affiliate level 3
institution
￿ Systemic treatments given under the supervi-
sion of a physician with appropriate oncology
training
￿ Access to specialized services and to provid-
ers with a formalized linkage to the RSTP are
ensured
￿ Level 3 (Affiliate)
￿ Systemic treatments given under direct super-
vision of an on-site staff medical oncologist,
hematologist, or gynecologic oncologist
￿ Limited teaching and research responsibilities
￿ Level 2 (ICP)
￿ Systemic treatments given in a setting provid-
ing radiation treatment services and capable
of providing most complex systemic treat-
ments, including concurrent head-and-neck
chemoradiation or radiolabelled conjugates (or
both)
￿ Limited teaching and research responsibilities
￿ Level 1 (ICP)
￿ Academic institutions with teaching and re-
search responsibilities
￿ Experimental investigational new drug (IND)
program (IND phase I and II trials) with highly
developed clinical trials infrastructure—for
example, participation in the National Cancer
Institute of Canada Clinical Trials Group IND
program and Princess Margaret Hospital/U.S.
National Institutes of Health phase II new drug
consortium
￿ Responsible for training future health care pro-
fessionals, including oncologists (subspecialty
residents and fellows)VANDENBERG et al.
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3.3 Defining Features for Each Level in the
Framework
The goal of the RSTP is to ensure safe, standardized,
evidence-based care across the regions and equitable
access to systemic treatment. Tables I–VIII delineate
the defining features by level in the areas of type of
care, health care providers, education, service type and
complexity, volumes, quality assurance and safety, fa-
cility requirements, and administrative responsibilities.
Definitions for key terms are provided in Appendix A.
4. DISCUSSION AND CONSENSUS
The Regional Models of Care Systemic Treatment
Project Team used the modest evidence that was
available from the published literature and the
environmental scan and the expert opinion of the mem-
bership to reach consensus on the defining features
for the organization and for delivery of systemic can-
cer treatment.
For several years, Cancer Care Ontario regional
networks delivered systemic treatment, particularly in
rural areas, under a hub-and-spoke model; however,
this delivery was accomplished without regional gov-
ernance or management authority 17. The provincial
standard of care now is the new integrated regional
systemic treatment model, with all its defining ele-
ments (Figure 1), which is being implemented with
the goal of improving equitable access to appropriate
evidence-based and coordinated cancer services. Ex-
isting regional cancer programs and new ones currently
being developed in Ontario will be expected to meet
the model requirements.
FIGURE 1   Regional model for quality systemic treatment. (Adapted from the Champlain Regional Cancer Surgery Model, 2006 14.)
TABLE I Type of systemic treatment care
                                       Complexity Level 1 Level 2 Level 3 Level 4
(ICP)( ICP) (Affiliate) (Satellite)
Experimental investigational new drug program Yes No No No
Concurrent head-and-neck chemorads, or radiolabelled conjugates, or both Yes Yes No No
Oncologist on site determines treatment plan Yes Yes Yes No
All other systemic treatment Yes Yes Yes Yes
ICP = integrated cancer program; chemorads = chemotherapy plus radiation therapy.PRACTICE GUIDELINE SERIES
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TABLE II   Health care providers and their roles
All levels Where the standard identifies that services are to be provided in a multidisciplinary environment, all providers required for
     the service at a particular level are available or readily accessible.
All patients being considered for systemic treatment must be assessed by an oncologist.
All treatment plans are recommended by and parenteral systemic treatment is prescribed by the consulting oncologist.
Individual treatments as part of an approved course may be ordered by a family physician or internist with oncology training.
Ongoing care must be coordinated with the consulting oncologist.
Only registered nurses with appropriate chemotherapy certification may administer parenteral drugs.
Only pharmacists or pharmacy technicians will prepare systemic treatment.
Oncologists Level 4 (Satellite) Access to oncologist from a level 1, 2, or 3 hospital is required to determine and recommend
     the treatment plan, to manage disease status, and to discuss patient management issues with
      the health care team.
Level 3 (Affiliate) One or more oncologists are on staff and on site.
Mentor family physicians/internists.
Provide limited teaching and research.
Level 2 (ICP) Level 3, plus:
Developed specific subspecialized practices.
Level 1 (ICP) Level 2, plus:
Have academic responsibilities, including teaching and research.
Family Level 4 (Satellite) Supervise intravenous systemic treatment administration with one physician on site or readily
   physicians/      available (within 15 minutes) during the drug administration time.
   internists Consult oncologists regarding patient management issues (for example, dose alteration).
Assess and manage toxicity.
Participate in education programs related to the management of patients receiving systemic
     treatment.
Level 3 (Affiliate) Same as level 4.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2.
Nurses Level 4 (Satellite) Administer systemic treatment, including monitoring and intervening for side effects and
     reactions, and provide supportive care to the patient.
Provide patient education related to planned systemic treatment in collaboration with
     pharmacist and physicians.
Communicate with ICP or affiliate team members and collaborate with supervising physicians
     as necessary.
Manage symptoms.
Level 3 (Affiliate) Level 4 plus:
Plans to implement advanced oncology nurse.
Level 2 (ICP) Level 3 plus:
Specialized oncology nurses working towards the national certification—Certified in Oncology
     Nursing (Canada)—within 5 years of employment.
Advanced oncology nurse to manage selected patient populations independently or interde
     pendently with oncologists.
Level 1 (ICP) Same as level 2.
Pharmacists Level 4 (Satellite) Review and verify systemic treatment orders and supervise the preparation and dispensing of
      systemic treatment.
Consult with ICP or affiliate pharmacist as required.
Manage the reimbursement process for new drug funding program (pharmacist or pharmacy
     technician).
Provide patient education related to medications in collaboration with nurses and physicians.
Supervise and manage dispensing and documentation of clinical trials.
Level 3 (Affiliate) Same as level 4
Level 2 (ICP) Level 3, plus:
Provide support and consultation to regional systemic treatment program.
Provide clinical services (dedicated oncology pharmacists).
Level 1 (ICP) Same as level 2.
Pharmacy Level 4 (Satellite) Prepare systemic treatment under supervision of a pharmacist.
   technicians Level 3 (Affiliate) Same as level 4.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2.
ICP = integrated cancer program.VANDENBERG et al.
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TABLE III   Education of health care providers
All levels Minimum standards are met for orientation and for annual continuing education and mentoring in systemic treatment for all
   of care      staff working in oncology services.
Providers are competent to provide the designated level of service and have ongoing education to maintain that competence.
Registered nurses meet organizational policy and standards to be certified in chemotherapy administration.
Oncologists Level 4 (Satellite) —
Level 3 (Affiliate) Take ongoing continuing medical education per the Royal College of Physicians and Surgeons of
     Canada.
Participate in multidisciplinary cancer conferences as required.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2.
Family Level 4 (Satellite) Take initial orientation and annual continuing medical education.
   physicians/ Mentoring by an oncologist should be available.
   internists Relevant training for systemic treatment being delivered.
Know the systemic treatment guidelines and standards, and regional policies and procedures.
Participate in multidisciplinary cancer conferences as required.
Level 3 (Affiliate) Same as level 4.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2
Nurses Level 4 (Satellite) Registered nurse certified for the delivery of systemic treatment.
Working towards Certified in Oncology Nursing (Canada) or recertification, or both.
Educated in central venous access device management and selection, certification. Annual
     update required.
Oriented to and practicing according to the
  ￿ safe handling of cytotoxic agents standards, and
  ￿ central venous access devices guidelines.
Participation in multidisciplinary cancer conferences encouraged.
Additional ongoing education required to match treatment type and complexity.
Level 3 (Affiliate) Level 4, plus:
Registered nurse specialized in oncology, certified in systemic treatment administration, and
     annually updated in guidelines and procedures.
Plans to implement advanced oncology nursing roles.
Level 2 (ICP) Level 3, plus:
Specialized oncology nurses working towards Certified in Oncology Nursing (Canada);
     certification should be obtained within 5 years of new employment.
Advanced oncology nurse (clinical nurse specialist or acute care nurse practitioner, Master’s
     preparation) with additional knowledge and skills in managing patients on systemic
     treatment.
Additional education for nurses managing transplant patients.
Level 1 (ICP) Same as level 2.
Pharmacists Level 4 (Satellite) Specialized training in oncology.
Regional systemic treatment program should provide a training or certification program for staff
     involved in the handling of cytotoxic agents and should have a policy on retraining. Programs
     may be held at or in collaboration with an ICP or affiliate institution.
Training may include institutional training or orientation program for oncology pharmacists,
     continuing education programs or courses, oncology pharmacy review courses (for example,
     American Society of Health-System Pharmacists oncology review course), preceptorship
     programs.
Level 3 (Affiliate) Same as level 4.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2.
Pharmacy Level 4 (Satellite) Specialized training in the preparation of systemic treatment doses.
   technicians Regional systemic treatment program should provide a training or certification program for staff
     involved in the handling of cytotoxic agents and have a policy on retraining. Programs may
be      held at or in collaboration with an ICP or affiliate institution.
Level 3 (Affiliate) Same as level 4.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2.
ICP = integrated cancer program.PRACTICE GUIDELINE SERIES
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TABLE IV   Service type and complexity
All levels Services are provided in the most appropriate setting, where patients can be assured the best-quality outcomes.
   of care Each level has access to the other levels where necessary, for consultation or for transfer for service delivery.
Service See the disease-site-specific Cancer Care Ontario core and core restricted regimens as an example: www.cancercare.on.ca/
   type      index_chemoRegimensbyDisease.htm.
Clinical trial drugs will be given at level 1, 2, or 3, or at level 4 under the supervision of oncologist.
Levels 4 (Satellite, Per the example of Cancer Care Ontario core and core restricted regimens.
  and 3 Affiliate)
Level 2 (ICP) Per the example of core and core restricted regimens, plus:
Concurrent chemotherapy and radiation.
Radiopharmaceuticals.
Level 1 (ICP) Same as level 2.
Complexity Level 4 (Satellite) Low to high complexity.
Assessment for and management and coordination of central venous access devices (such as a
     peripherally inserted central catheter or Port-A-Cath).
Drugs with a high risk of hypersensitivity reaction at first dose will be given only at level 4
     centres as agreed upon by the regional systemic treatment program.
Delivery of systemic treatment in presence of comorbidity or significant organ dysfunction
     that increases risk of toxicity and need for dose adjustments, if agreed upon by regional
     systemic treatment program.
Monitoring and management of hypersensitivity reactions.
Level 3 (Affiliate) Same as level 4, plus:
Delivery of first-dose high-risk drugs.
High complexity.
Level 2 (ICP) Level 3, plus:
Provision of on-site direct coordination and supervision of medical and radiation treatment.
Pathology consultation on site.
Level 1 (ICP) Same as level 2
Patient Level 4 (Satellite) If possible, on-site patient education program that meets the Cancer Care Ontario standards.
   education Level 3 (Affiliate) Same as level 4, plus:
Adhere to Cancer Care Ontario patient education standards.
Level 2 (ICP) Level 3, plus:
Patient education program related to radiation treatment.
Level 1 (ICP) Level 2, plus:
Patient education related to investigational treatments
Supportive Level 4 (Satellite) Access to supportive care services to address specific patient needs.
   care Level 3 (Affiliate) Same as level 4.
Level 2 (ICP) Comprehensive supportive care expertise as part of ICP.
Level 1 (ICP) Same as level 2.
Clinical Level 4 (ICP) If clinical trials are conducted at the institution, they must be under the direction of an
   trials      oncologist.
Family physicians or internists with oncology training may be co-investigators.
Specific clinical trial education for patients and health care providers.
Level 3 (Affiliate) Specific clinical trial education for patients and health care providers.
Clinical trials including phases II and III.
Level 2 (ICP) Same as level 3
Level 1 (ICP) Same as level 2, plus:
Investigational new drug program with phase I or II drugs, or both.
ICP = integrated cancer program.
TABLE V    Service volumes
All levels The location has sufficient patient volume to maintain competency and skills of professional providers to address the
 of care      acuity and complexity of the treatment modalities and to provide cost-effective use of resources and drugs.
The number of patients that can be treated will be affected by the complexity of the treatment regimens.
Staffing must be sufficient to provide safe, quality care at all times, including during vacation, illness, and so on.VANDENBERG et al.
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TABLE VI   Quality assurance and safety
All levels Cancer care includes management of complications of therapy.
   of care All centres will follow the safe handling of cytotoxic agents standards.
Up-to-date guidelines from the regional systemic treatment program are available for staff for relevant disease sites and
     relevant symptom management.
Training and guidelines include management of oncology emergencies.
Access to specialized centres (ICP level 1 or 2 or affiliate level 3) for support of quality and standards.
Provision of systemic treatment in the most effective manner.
Safe Level 4 (Satellite) Policies and education programs available for all staff involved in systemic treatment, including
   handling      storage, transport, spill management, preparation, administration, and waste disposal.
Level 3 (Affiliate) Same as level 4.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2.
Patient Level 4 (Satellite) Patient safety program includes review of all medication adverse events and system improvement.
   outcomes Quality indicators:
  ￿ Assessment of toxicities and documentation of adverse reaction.
Level 3 (Affiliate) Same as level 4.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2.
Organization Level 4 (Satellite) Multidisciplinary cancer conference participation encouraged.
   outcomes Quality indicators:
  ￿ Track volume of patients treated.
  ￿ Other indicators such as monitoring adherence to guidelines.
Level 3 (Affiliate) Level 4, plus:
Multidisciplinary cancer conference participation required.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2.
System Level 4 (Satellite) Quality indicators:
   outcomes   ￿ Percentage of patients treated close to home.
Level 3 (Affiliate) Level 4, plus:
Monitoring systemic treatment wait times.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2.
ICP = integrated cancer program.
Although developed in the Ontario context, this
model may, we believe, be useful in other provinces.
The goal of the model is to ensure that, regardless of
where in a province a patient receives systemic treat-
ment, the same standard of care is guaranteed: the
patient receives appropriate care in the appropriate
setting within the appropriate time frame by clinicians
with the expertise to offer the services. A regional pro-
gram model replaces a traditional hub-and-spoke model
and better reflects the relationships between all part-
ners delivering systemic treatment.
In the new model, the RSTP assumes regional lead-
ership for the delivery of systemic treatment, with sup-
port from the provincial cancer organization. Although
most regional authorities in Canada (for example, lo-
cal health integration networks, district health coun-
cils, health authorities, or health regions) have ICPs, it
is important to acknowledge that, to best meet patient
needs, cross-regional collaboration must also be con-
sidered in the planning of RSTPs. In addition, regional
authorities without ICPs also exist, and therefore re-
gional cancer services must be planned through a neigh-
bouring ICP. Under the RSTP, systemic treatment ICPs,
affiliates, and satellites would work collaboratively to
ensure safe, evidence-based care that maximizes the
capacity of care given across the region, while ensur-
ing appropriate high-quality care.
5. CONCLUSIONS
The structure for systemic treatment delivery in am-
bulatory centres provides a comprehensive regional and
provincial framework. This framework has been
formed through a combination of evidence and expert
consensus. Consensus was achieved through a small
working group and the larger Regional Models of Care
Systemic Treatment Project Team. The framework
outlines the four levels (institution types) of care that
are recommended for the delivery of systemic treat-
ment. A hospital is not prevented from moving up toPRACTICE GUIDELINE SERIES
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TABLE VII   Facility requirements
All levels The necessary infrastructure is in place to provide the service level.
   of care
Clinic space Level 4 (Satellite) Dedicated systemic treatment area adequate for volume of treatment visits.
Adequate space to provide clinical trials if applicable.
Level 3 (Affiliate) Same as level 4.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Level 2, plus:
Dedicated clinical trials infrastructure on site.
Clinic Level 4 (Satellite) Computer, facsimile, and telephone accessibility.
   equipment Computer software available to provide computerized physician order entry.
Level 3 (Affiliate) Same as level 4
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2.
Systemic Level 4 (Satellite) Oxygen.
   treatment Biological safety cabinet (class 2) and externally vented.
   and facility Appropriate tubing, Luer-lock syringes.
   safety Intravenous equipment for parenteral therapy.
   equipment Intravenous equipment for ambulatory or inpatient infusional therapy (pumps).
Personal protective equipment for staff who are handling systemic treatment or waste.
Spill kits and supplies for decontamination.
Emergency resuscitation equipment (for example, crash cart, other emergency supplies, drugs,
     oxygen, and suction) in case of cardiorespiratory arrest or anaphylaxis.
Supportive drugs for treatment of extravasation.
Designated clinical trial storage if doing clinic trials.
Level 3 (Affiliate) Same as level 4.
Level 2 (ICP) Same as level 3.
Level 1 (ICP) Same as level 2.
Institutional Level 4 (Satellite) Emergency department.
   facilities Pharmacy for secure storage and preparation of systemic treatment drugs.
Access to inpatient beds for oncology patients.
Access to local specialized diagnostic imaging (computed tomography, ultrasound, nuclear
     medicine), laboratory tests, and pathology for the monitoring of systemic treatment.
Access to intensive care unit.
Access to facility for insertion of central venous catheters or Port-A-Cath access devices.
Potential for videoconferencing, remote Web-based teaching, and patient management as part of
     multidisciplinary cancer conference.
Level 3 (Affiliate) Same as level 4, plus:
Intensive care unit and specialized diagnostic imaging on site.
Level 2 (ICP) Level 3, plus:
Radiation therapy services on site.
Pathology services on site.
Magnetic resonance imaging on site.
Specialized diagnostic imaging on site.
Level 1 (ICP) Same as level 2.
ICP = integrated cancer program.
the next level, provided that all the model requirements
are met and that the RSTP agrees to the move. The
present work provides a framework for all hospitals to
meet the same standards and, at the same time, to achieve
quality care and service when administering systemic
treatment. Although the present article has been cre-
ated to sustain the Ontario Cancer Care network in pro-
viding safe and accessible care, we believe that it is
applicable to, and useful for, other jurisdictions.
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APPENDIX A
Definitions
Advanced Oncology Nurse:   The advanced oncology
nurse is prepared at the Master’s level (MScN or equiva-
lent). Additional certification as an acute care nurse
practitioner (or other levels) may be acquired either
within the graduate program or as a postgraduate course
and certification. The domains of the advanced oncol-
ogy nurse include
￿ advanced clinical practice,
￿ education,
￿ research,
￿ scholarly/professional leadership, and
￿ organizational leadership 15.
Certification in Systemic Treatment Administration
(Certified in Chemotherapy):   No registered nurse in
Ontario should administer intravenous systemic treat-
ment until and unless that nurse has received additional
education and has demonstrated competency in the
delivery of these cytotoxic agents. This requirement is
specific to the delivery of chemotherapy and is not to
be confused with the national examination process for
certification as an oncology nurse through the Cana-
dian Nurses Association.
Complexity:   Complexity is determined by the
preparation and administration requirements for sys-
temic treatment, risk of immediate grade 3 or 4
toxicities, medical condition of the patient, or use of
investigational agents or new agents just approved for
which little long-term toxicity data are available.
Institutional Facilities:   Hospitals, clinics, or of-
fices as outlined in the facility requirements element.
Integrated Cancer Program (ICP):   A multidisci-
plinary in-and-out patient cancer program including
medical, radiation, and surgical oncology. The ICP will
also provide research, education, and organizational
leadership for the regional cancer program.
Oncologist:   A physician with subspecialty train-
ing in the administration of systemic treatment, recog-
nized by the Royal College of Physicians and Surgeons
of Canada, including medical oncologists, hema-
tologists, and gynecologic oncologists.
Quality Indicator:   A specific, measurable, at-
tainable, relevant, time-framed outcome from the pa-
tient, organizational, or system perspective to assess
performance 16.
Regional Systemic Treatment Program (RSTP):   An
agreed-upon relationship between satellites, affiliates,
and ICPs.
Specialized Oncology Nurse:   A nurse who has a
combination of expanded education focused on cancer
care and experience such as 2 years in a setting in
which the primary focus is cancer care delivery. The
specialized oncology nurse might acquire specialty
education in a variety of ways—for example, enrol-
ment in an undergraduate nursing program, comple-
tion of an oncology certificate program, distance
specialty education (such as that offered in adult andVANDENBERG et al.
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pediatric oncology nursing), or registration in and com-
pletion of the certification exam offered by the Cana-
dian Nurses Association and attainment of the
distinction Certified in Oncology Nursing (Canada).
The specialized oncology nurse works in a spe-
cialized inpatient setting such as an oncology unit or
bone-marrow transplant unit, an ambulatory setting
focused on the delivery of cancer care, a screening
program, or a supportive care setting or community
setting offering palliative care. The individual’s en-
hanced specialty knowledge and skill can be utilized
in many environments to manage symptoms and side
effects of treatment, to counsel patients in coping strat-
egies, to teach self-care behaviours, and to monitor
responses to treatment and nursing interventions 15.
Systemic Treatment:   Any oral or parenteral, hor-
monal, biologic, chemotherapeutic, or radiopharma-
ceutic anticancer agent.